Oral melphalan for the treatment of relapsed canine lymphoma.

about

Metabolic Abnormalities Detected in Phase II Evaluation of Doxycycline in Dogs with Multicentric B-Cell Lymphoma.

P2860

Q55058455-FCB0A9C7-8FFD-428F-A749-D20E7DF49A7F

P2860

Oral melphalan for the treatment of relapsed canine lymphoma.

Item

http://www.wikidata.org/entity/Q44875615

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Oral melphalan for the treatment of relapsed canine lymphoma.

@en

Oral melphalan for the treatment of relapsed canine lymphoma.

@nl

type

Item

label

Oral melphalan for the treatment of relapsed canine lymphoma.

@en

Oral melphalan for the treatment of relapsed canine lymphoma.

@nl

prefLabel

Oral melphalan for the treatment of relapsed canine lymphoma.

@en

Oral melphalan for the treatment of relapsed canine lymphoma.

@nl

P1476

Oral melphalan for the treatment of relapsed canine lymphoma

@en

P2093

M L Hauck

http://www.w3.org/2001/XMLSchema#string

P R Hess

http://www.w3.org/2001/XMLSchema#string

S E Suter

http://www.w3.org/2001/XMLSchema#string

P2860

Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.

Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.

Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.

Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).

Dacarbazine as single-agent therapy for relapsed lymphoma in dogs.

Efficacy and toxicity of BOPP and LOPP chemotherapy for the treatment of relapsed canine lymphoma.

Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013).

Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document.

Oral melphalan kinetics.

Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological disease.

P304

E123-E129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/VCO.12356

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

M L Mastromauro

P577

2017-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28941072

http://www.w3.org/2001/XMLSchema#string

Oral melphalan for the treatment of relapsed canine lymphoma.

about

P2860

P2860

Oral melphalan for the treatment of relapsed canine lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698